6/28/23, 12:45 AM ASPRE Pathway Feedback Search Clinical Topics Home Studies ASPRE ASPRE Disease Preeclampsia Trial question What is the effect of aspirin in women with singleton pregnancies who are at high risk for preterm preeclampsia? Study design Multi-center Double blinded RCT Population 1776 female patients Inclusion criteria: women with singleton pregnancies who are at high risk for preterm preeclampsia Key exclusion criteria: unconscious or severely ill status, learning difficulties or serious mental illness, major fetal abnormality identified at the time that scanning was performed at 11-13 weeks of gestation, von Willebrand's disease, peptic ulceration, hypersensitivity to aspirin, long-term use of nonsteroidal antiinflammatory medication Interventions N=798 aspirin (150 mg per day from 11-14 weeks gestation until 36 weeks of gestation) N=822 placebo (matching placebo from 11-14 weeks of gestation until 36 weeks of gestation) Primary outcome Preterm preeclampsia 4.3 4.3 % 3.2 % 2.1 % 1 6 https://web.pathway.md/studies/recWaqSbOc30GLikP 1/2 6/28/23, 12:45 AM ASPRE Pathway 1.6 Significant decrease 1.1 % NNT = 37 0.0 % Aspirin Placebo Significant decrease in preterm preeclampsia (1.6% vs. 4.3%; OR 0.38, 95% CI 0.2 to 0.74) Secondary outcomes No significant difference in stillbirth or death (1% vs. 1.7%; OR 0.59, 99% CI 0.19 to 1.85) Safety outcomes No significant difference in neonatal or other adverse events. Conclusion In women with singleton pregnancies who are at high risk for preterm preeclampsia, aspirin was superior to placebo with respect to preterm preeclampsia. Reference Rolnik DL, Wright D, Poon LC et al. Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia. N Engl J Med. 2017 Aug 17;377(7):613-622. Open reference URL https://web.pathway.md/studies/recWaqSbOc30GLikP 2/2